Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2010 Feb;11(3):423-39. doi: 10.1517/14656560903508762.

Pharmacogenetic considerations in the treatment of psychiatric disorders.

Author information

  • 1University of Pennsylvania School of Medicine, Center for Neurobiology and Behavior, Department of Psychiatry, Translational Research Laboratories, 125 South 31st Street, Room 2213, Philadelphia, PA 19104, USA. lohoff@mail.med.upenn.edu

Abstract

IMPORTANCE OF THE FIELD:

Despite continued efforts to optimize pharmacological treatment for individuals with psychiatric disorders, efficacy and tolerability of medication remains highly variable. In addition to clinical heterogeneity, diagnostic uncertainty, environmental, social factors, and genetic factors have been identified as playing an important role in the interindividual differences in therapeutic and toxic drug effects.

AREAS COVERED IN THIS REVIEW:

This article describes recent developments in the field of psychiatric pharmacogenetics and focuses on antidepressant, antipsychotic, anticonvulsant, and mood-stabilizing drugs.

WHAT THE READER WILL GAIN:

Recent findings from pharmacogenetic clinical trials are reviewed and clinical implications are discussed.

TAKE HOME MESSAGE:

Although current data are too sparse to allow the development of guidelines for using pharmacogenetic testing in routine clinical practice, the field of psychiatric pharmacogenetics is rapidly developing and identification of genetic biomarkers that predict therapeutic response and risk of side effects will ultimately help the practitioner to choose effective and safe treatment for patients suffering from psychiatric disorders.

PMID:
20102306
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk